Formed by a growing team of Cambridge scientists and geneticists, the company provides an independent platform for clinicians to quickly compare and order specialist genetics services, advancing the uptake of genomic medicine into the healthcare market.
The £350,000 seed round is led by Abcam founder and life science investor Jonathan Milner, who joins the board of directors as company chairman. Further funds are contributed by Dr Darrin Disley (Horizon Discovery), Dr Chris Torrance (Phoremost), Simon Thorpe (Delta2020), Martlet and other individual investors.
fills a great need for accessible genetic testing and will significantly impact the lives of patients with rare disease, cancer and neurological conditions,” says Dr Milner. “It shows real potential to scale quickly and become the market leader in this space. I’m impressed by the way the team has created the platform over the past year and look forward to helping them make their ambitious longer-term plans a reality.”
Clinicians are already using GeneAdviser
to order specialist genetic tests from the NHS Regional Genetics Centre at Addenbrooke’s Hospital in Cambridge. This funding will allow GeneAdviser to expand the ordering platform into a broader marketplace, making it easier for clinicians worldwide to select and order genetics services.